Lv2
194 积分 2022-12-09 加入
Targeting the tumour vasculature: from vessel destruction to promotion
2天前
已完结
Ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated non-small-cell lung cancer after disease progression on EGFR tyrosine kinase inhibitor therapy (HARMONi): a multicentre, randomised, double-blind, phase 3 trial
15天前
已完结
Efficacy and safety of immune checkpoint inhibitors for individuals with advanced EGFR-mutated non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitors: a systematic review, meta-analysis, and network meta-analysis
16天前
已完结
Early-Stage NSCLC: Novel Surgical Techniques and Neoadjuvant, Adjuvant, and Perioperative Therapies
19天前
已完结
Bispecific antibodies: a mechanistic review of the pipeline
1个月前
已完结
Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer
1个月前
已完结
The present and future of bispecific antibodies for cancer therapy
1个月前
已完结
Navigating the landscape of EGFR TKI resistance in EGFR-mutant NSCLC — mechanisms and evolving treatment approaches
1个月前
已完结
Opportunities and challenges in the development of evolving EGFR inhibitors to overcome EGFR TKIs resistance
1个月前
已完结
皖公网安备34019202002308
